Thiruvananthapuram, Dec 5 (UNI) In a path-breaking genetic study that could significantly reduce the risk of organ rejection and other medical complications, scientists of the Rajiv Gandhi Centre for Biotechnology (RGCB) here have formulated a method to predict the optimal dose of an immunosuppressant drug given to kidney transplant patients.
The dose prediction study was focused on the immunosuppressant drug tacrolimus, which is given to a kidney, heart or liver transplant patients to lower the body's immunity and thereby considerably reducing the chances of organ rejection.
For maximum effectiveness, the drug level has to be maintained at an optimum concentration in the blood, especially during the initial period after transplantation, a release said here on Sunday.